GAPVAC
Glioma Actively Personalized Vaccine Consortium
| Coordinatore |
Organization address
address: PAUL EHRLICH STR 15 contact info |
| Nazionalità Coordinatore | Non specificata |
| Sito del progetto | http://www.gapvac.eu |
| Totale costo | 7˙918˙396 € |
| EC contributo | 5˙970˙436 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-11-01 - 2017-01-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
IMMATICS BIOTECHNOLOGIES GMBH
Organization address
address: PAUL EHRLICH STR 15 contact info |
DE (TUEBINGEN) | coordinator | 1˙588˙636.00 |
| 2 |
BIONTECH AG
Organization address
address: HOLDERLINSTRASSE 8 contact info |
DE (Mainz) | participant | 1˙143˙277.00 |
| 3 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 908˙858.40 |
| 4 |
BCN PEPTIDES S.A
Organization address
address: "Carretera Comarcal c-244, km. 22, Pol. Ind. Els Vinyets-Els Fogars, Sector 2" contact info |
ES (Barcelona) | participant | 499˙360.00 |
| 5 |
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
Organization address
address: TECHNION CITY - SENATE BUILDING contact info |
IL (HAIFA) | participant | 303˙750.00 |
| 6 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 297˙108.00 |
| 7 |
UNIVERSITAETSKLINIKUM HEIDELBERG
Organization address
address: IM NEUENHEIMER FELD 672 contact info |
DE (HEIDELBERG) | participant | 251˙107.20 |
| 8 |
REGION HOVEDSTADEN
Organization address
address: KONGENS VAENGE 2 contact info |
DK (HILLEROD) | participant | 246˙108.00 |
| 9 |
INSTITUT CATALA DE LA SALUT
Organization address
address: GRAN VIA DE LES CORTS CATALANES 587 contact info |
ES (BARCELONA) | participant | 231˙108.00 |
| 10 |
UNIVERSITE DE GENEVE
Organization address
address: Rue du General Dufour 24 contact info |
CH (GENEVE) | participant | 231˙108.00 |
| 11 |
UNIVERSITY OF SOUTHAMPTON
Organization address
address: Highfield contact info |
UK (SOUTHAMPTON) | participant | 231˙108.00 |
| 12 |
IMMUNOLOGISCHE KREBS-THERAPIE EV
Organization address
address: LANGENBECKSTRASSE 1 contact info |
DE (MAINZ) | participant | 37˙799.00 |
| 13 |
UNIVERSITY OF GLASGOW
Organization address
address: University Avenue contact info |
UK (GLASGOW) | participant | 1˙108.34 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Glioblastoma (GBM) is a rare (2-3 incidences in 100,000) and fatal disease. Each year, approximately 13,000 new cases of GBM are diagnosed in Europe. The 5-year survival rate of this highly aggressive tumor entity under conventional therapy is less than 6%. Currently available therapeutic options neglect the individuality of each patients’ disease and only temporarily influence tumor progression with poor effect on overall survival. Introduction of novel highly innovative personalized approaches would have tremendous impacts for the life course of affected patients without additive toxicities. Active cancer immunotherapy aims to trigger the patients´ immune system, specifically cytotoxic T lymphocytes (CTLs) and T helper cells, to defend the body against the cancerous disease. The Glioma Actively Personalized Vaccine Consortium (GAPVAC) aims to conduct a highly innovative pioneering project with active personalized immunotherapy to improve patient treatment. In a Phase I/II study at the center of this proposal, glioblastoma patients will receive a fully personalized peptide-based vaccine as a result of full-genome sequencing and complete peptidomics analysis of the patient’s tumor. Thus, the latest developments in next-generation sequencing, proteomics, immunology, biomarker research and small-scale GMP peptide manufacturing will be uniquely combined to deliver the next generation of personalized medicine to cancer patients. GAPVAC’s goal is to test safety, feasibility and efficacy (biological and early clinical) of this totally novel, completely personalized approach of immunotherapy. GAPVAC is therefore specifically answering the call HEALTH.2012.1.2-1 Development of technologies with a view to patient group stratification for personalized medicine applications by a 4 years project.'
Altri progetti dello stesso programma (FP7-HEALTH)
UROMOL (2008)
Prediction of bladder cancer disease course using risk scores that combine molecular and clinical risk factors
Read More